What sits inside pharmacovigilance outsourcing?
The intake and processing of adverse event reports so your safety physicians can focus on assessment. Teams receive reports by phone, email, web form and partner feeds, check for the four minimum criteria of a valid case, triage seriousness and timelines, enter cases into the safety database, code events and products with MedDRA and WHO Drug, write narratives, send follow-up requests and support literature screening. Medical review, causality and submission decisions stay with your safety team. Answering product questions from doctors and patients is on pharma medical information.
Safety work is volume against a clock. Every valid case has a deadline from the day anyone in the company first hears about it.
Inside the pharmacovigilance team: four jobs.
Most companies start with intake and non-serious case processing, then move serious cases and literature screening across.
Receive reports from patients, healthcare professionals and partners by phone, email and web, around the clock, and record day zero.
Check case validity, assess seriousness and expectedness for routing, enter data, code with MedDRA and WHO Drug and check duplicates.
Write clear case narratives, request missing information from reporters and add follow-up to the case.
Screen articles for reportable cases and safety information, and record what was found for your safety team.
The buyers behind outsourced pharmacovigilance.
Companies that hold marketing authorizations or run clinical studies and must collect, process and report adverse events for their products.
How the desk is run
The team works in your validated safety database to your safety data exchange agreements and SOPs. Day zero is recorded on every case, and triage decides the clock before anything else happens.
Two places outsourced pharmacovigilance loses time.
Both are fixable before go-live.
How an adverse event case moves
Every case passes the same checkpoints. Medical judgment stays with your safety physicians.
Who outsources pharmacovigilance, and where timelines slip.
Growing product portfolios and case volume ahead of headcount.
Post-marketing safety obligations starting for the first time.
High volumes of non-serious cases and literature reports.
Peaks from new clients and study close-outs.
2026 rates by role — fully loaded, per hour
Ask each vendor to price against your monthly case volume, share of serious cases and literature scope. Rates confirmed per engagement.
Scope my safety team →Generalist BPO or a vetted pharmacovigilance team: what changes.
Where a general medical back office and a pharmacist-led safety team differ.
Pharmacovigilance outsourcing in the Philippines: drug safety at volume
Pharmacovigilance outsourcing to the Philippines gives pharma and biotech companies a team for collecting and processing adverse event reports. The work is detailed and time-bound: every valid report must be captured, triaged, coded and processed so serious cases can be reported to regulators on time.
The Philippines has one of Asia’s largest pools of licensed pharmacists, nurses and medical technologists, and many already work in drug safety for global companies. That clinical background matters for triage and coding. Hubs in Manila, Cebu and Clark provide around-the-clock intake for US and EU reporters. For the wider picture, see our guides to FDA compliance in pharma outsourcing and how pharma outsourcing is changing.
Intake, validity and triage
A valid case needs four elements: an identifiable patient, an identifiable reporter, a suspect product and an adverse event. The intake team checks for these, records day zero and captures as much detail as the reporter can give, including product batch numbers and timelines.
Triage comes next. Serious and unexpected cases from post-marketing sources in the US must reach the FDA within 15 calendar days under 21 CFR 314.80, and similar timelines apply in the EU under Good Pharmacovigilance Practices. The team routes expedited cases first and flags them for medical review.
Case processing, coding and narratives
Case processing turns a report into structured data. The team enters cases into your safety database, codes events, indications and medical history with MedDRA and products with WHO Drug, checks for duplicates and writes a narrative that tells the medical reviewer what happened, in order.
Consistency matters as much as speed. Good vendors keep coding conventions, review a sample of every processor’s cases and track errors by type. Cases are prepared for E2B(R3) electronic transmission, but submission decisions stay with your safety and regulatory staff.
Aggregate reports and signal detection support
Beyond individual cases, marketing authorization holders must prepare periodic aggregate reports, such as PSURs and PBRERs for the EU and other markets and periodic reports for the FDA, and run ongoing signal detection. Support teams compile line listings, run data extracts from the safety database, prepare tables and draft sections under the direction of safety physicians, who write the benefit-risk evaluation and conclusions.
Signal detection support includes preparing disproportionality outputs, literature summaries and case series for review. Teams keep a calendar of report deadlines across products and markets so nothing is missed. See pharma outsourcing for wider support and life sciences outsourcing for the shared quality framework across regulated functions.
Local literature, local affiliates and global coverage
Global safety programs must screen local-language medical literature and receive cases from local affiliates, distributors and partners in every market. Support teams run local literature searches, translate relevant articles, track affiliate case submissions and reconcile partner exchanges under safety data exchange agreements. Gaps in local coverage are a common inspection finding.
Multilingual teams in the Philippines cover many languages, with native or professional translators for less common ones. See multilingual back-office for document processing in other languages and medical information for the inquiry desks that feed safety cases.
Patient support programs and market research as case sources
Adverse events surface in places beyond spontaneous reports: patient support program calls, nurse educator visits, market research interviews, social media and digital channels. Each source must have a process to capture and forward events within timelines. Pharmacovigilance support teams train program staff, reconcile program records against the safety database and follow up on reports that lack minimum criteria.
Reconciliation between programs and the safety database is an expectation in inspections. See healthcare patient support for program operations and social media care for monitoring digital channels.
Inspection readiness and the PSMF
Regulators inspect pharmacovigilance systems, and the EU requires a Pharmacovigilance System Master File describing them. Support teams keep the PSMF annexes current, maintain training records, organize SOPs and compliance metrics and prepare evidence packs for inspections and partner audits. Late case submissions and weak reconciliation are common findings, so timeliness reports matter.
Responsibility for the PV system stays with the qualified person for pharmacovigilance and the safety team. See our compliance guide and clinical trial support for the pre-approval safety side.
Automation, AI and human review in case processing
Safety departments increasingly use automation to extract case data from source documents, suggest MedDRA codes and draft narratives. These tools can speed processing, but regulators expect validated systems and human review of outputs. Teams check automated entries against source documents, correct coding and narratives and log corrections so tools can be tuned.
Measuring how often automated outputs need correction shows whether tools are ready for wider use. See AI verification for human review of AI outputs and intelligent document processing for document automation.
Choosing a pharmacovigilance partner
When you compare vendors, ask about pharmacist and nurse qualifications, safety database experience, timeliness on similar case volumes, literature and affiliate coverage, inspection history and how they separate administrative work from medical review. Ask for sample SOPs and timeliness reports.
Vetted mid-sized Philippine providers usually start pharmacovigilance programs with 5 to 40 people and report case timeliness, data quality on review, follow-up completion, reconciliation discrepancies and inspection findings. See the healthcare and life sciences hub for related programs.
Follow-up, literature and the metrics that matter
Many first reports are incomplete. The team sends follow-up requests to reporters, tracks answers and adds them to the case, then closes the loop when no more information is expected. For literature, screeners review articles against your search strategy and identify reportable cases and other safety information.
Vetted mid-sized Philippine providers usually start pharmacovigilance programs with 6 to 20 pharmacist-led staff and report case processing timeliness, quality scores by processor, follow-up response rates and literature screening throughput. Your QPPV and safety physicians keep accountability for the system.
When pharmacovigilance should stay in-house.
How pharmacovigilance connects to the rest of healthcare.
Pharmacovigilance has its own page because case processing runs to regulatory timelines that medical information and trial support do not.
Adverse event intake, triage, case processing and follow-up.
Answering product questions from doctors and patients.
Pharma medical information →Recruitment, EDC data entry and eTMF support.
Clinical trial support →Also serving: pharmacovigilance sits in our Healthcare & Life Sciences hub. The sector page is pharma outsourcing, and product inquiries are on pharma medical information.
Related specialist pages: bioprocessing support.
What safety leaders ask before they outsource pharmacovigilance.
Straight answers to the questions that decide a pharmacovigilance engagement, from the principals who run them.
